NCT04080739View on ClinicalTrials.gov

Regional Block for Postoperative Free Flap Care

PHASE4CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

January 13, 2020

Primary Completion Date

March 1, 2022

Study Completion Date

March 1, 2022

Conditions
Pain Management
Interventions
DRUG

ropivicaine 0.2%

2-8 cc/hr of 0.2% ropivicaine given as a regional block via US-guided ipsilateral sciatic nerve block for fibula free flap patients or US-guided infraclavicular brachial plexus nerve block for forearm free flap patients.

Trial Locations (1)

35233

University of Alabama at Birmingham, Birmingham

All Listed Sponsors
lead

University of Alabama at Birmingham

OTHER

NCT04080739 - Regional Block for Postoperative Free Flap Care | Biotech Hunter | Biotech Hunter